Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

J&J’s proposed opioid settlement framework eclipses its $2B talc penalty

By Brian Buntz | June 3, 2021

Johnson & JohnsonThe Supreme Court’s decision to deny reviewing a Johnson & Johnson talc lawsuit leaves the company on the hook for paying $2.5 billion, or $2.1 billion in damages plus interest.

But the talc litigation development also serves as a reminder that the company faces multiple litigation risks — some related to opioid litigation. The company has a proposed opioid settlement framework recommending a $5 billion payment to settle outstanding litigation. “If finalized, this would considerably reduce uncertainty related to J&J’s opioid exposures,” concluded a recent Moody’s report.

The company had initially agreed to a $4 billion settlement framework in negotiations with state attorneys general. Last October, the company agreed to pay an additional $1 billion as part of that framework.

The Supreme Court’s denial of a talc verdict appeal will leave Moody’s Aaa rating for J&J unchanged. “The company’s financial flexibility remains very strong, with gross debt/EBITDA of 1.6x as of April 4, 2021, and reported cash and short-term investments of $24.6 billion,” Moody’s concluded.

Johnson & Johnson has denied wrongdoing related to either its sale of talc or opioids.

Also related to opioids, J&J is also appealing a $465 million judgment Oklahoma won against the company. Attorneys general there asked the Oklahoma Supreme Court in late 2020 to make Johnson & Johnson pay up to $9.3 billion to the state — some 20 times more than the initial $465 million settlement. The attorneys general recommended in an appeal brief that the company pay $465 million annually for 20 years “or until the trial court determines the [opioid] crisis has been abated, whichever comes first.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards